• Ionis signed a license deal with Recordati granting exclusive rights to develop and commercialize zilganersen for Alexander disease outside the U.S.
• Ionis kept U.S. commercialization rights, will lead global development; Recordati will handle ex-U.S. regulatory filings, commercialization, early access support.
• Ionis will receive an upfront payment of $30 million, milestone payments, tiered royalties up to the mid-20% range on annual net sales.
• Zilganersen is under FDA review with a PDUFA action date of Sept. 22.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260624743930) on June 25, 2026, and is solely responsible for the information contained therein.